Global Home Global Home
MEXICO

A New Era in Anti-Infectives

 

Latest News
..........................................

August 7, 2008
Oculus Innovative Sciences to Present at Canaccord Adams 28th Annual Global Growth Conference

August 5, 2008
Oculus Innovative Sciences Reports 59% Increase in First Quarter Product Revenue

July 29, 2008
Oculus Innovative Sciences Announces Fiscal First Quarter Financial Results and Corporate Update Release and Conference Call

July 16, 2008
Oculus Innovative Sciences' CEO and Founder Named One of Pharmaceutical Executive's 2008 "Emerging Pharma Leaders"

July 1, 2008
Oculus Innovative Sciences Announces Positive Results from Abstract Evaluating the Use of Microcyn® Technology in Treatment of Atopic Dermatitis

June 23, 2008
Oculus Innovative Sciences Announces Agreement With Bayer (Sichuan) Animal Health Co. Ltd. for Development of Microcyn® Technology Use in Chinese Animal Market

June 19, 2008
Oculus Innovative Sciences Announces Agreement with Bayer Australia Limited for Development of Microcyn® Technology Use in Australian Animal Market

June 17, 2008
Oculus Innovative Sciences Announces Development of Microcyn®-Based Hydrogel Formulation

June 16, 2008
Oculus Innovative Sciences Announces Breakthrough Antimicrobial Formulation for Over-The-Counter Non-Wound Market to be Launched in U.S. Without Pre-Approval by the FDA

June 11, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update

June 5, 2008
Oculus Innovative Sciences Announces Fiscal Fourth Quarter and Full Year 2008 Financial Results and Corporate Update Release and Conference Call

June 4, 2008
Oculus Innovative Sciences Files for Patent Protection on Breakthrough Wound Care Device to Accelerate Wound Healing

June 2, 2008
Oculus Innovative Sciences Announces Market Assessment of Near-Term Commercialization Opportunities in the United States for Dermacyn™ Wound Care

May 28, 2008
Oculus Innovative Sciences Announces Publication of Microcyn® Technology Post-Caesarean Section Wound Study in Indian Medical Gazette

May 15, 2008
Oculus Innovative Sciences to Participate in Third Congress of the World Union of Wound Healing Societies in Toronto

May 5, 2008
Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan for Launch of Microcyn® Technology

April 23, 2008
Oculus Innovative Sciences Appoints Michelle Carpenter, JD, RAC, as Vice President of Regulatory Affairs and Quality

April 17, 2008
Oculus Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature Series

April 15, 2008
Oculus Innovative Sciences Announces Publication of Microcyn® Technology Diabetic Wound Study in Journal of College of Physicians and Surgeons Pakistan

March 28, 2008
Oculus Innovative Sciences, Inc., Announces $13.9 Million Securities Offering

March 27, 2008
Oculus Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn® Technology

March 17, 2008
Oculus Innovative Sciences Announces Positive Results From Three Abstracts Evaluating the Use of Microcyn® Technology in Diabetic Foot Ulcers

March 14, 2008
Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

March 12, 2008
Oculus Innovative Sciences Announces Acceptance of Three Abstracts on the use of Microcyn® Technology in Diabetic Foot Ulcers by DFCon 08

March 11, 2008
Oculus Innovative Sciences to Announce Additional Phase II Data and Data from Two Recent International Studies at DFCon 08

February 27, 2008
Oculus Innovative Sciences Schedules Conference Call Today to Discuss Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 27, 2008
Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 14, 2008
Oculus Innovative Sciences to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference

February 7, 2008
Oculus Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and Clinical Update

February 5, 2008
Oculus Schedules Fiscal Third Quarter 2008 Financial Results Release and Conference Call

January 29, 2008
Oculus Innovative Sciences Announces Agreement with Animal Health International for North American Distribution of Microcyn®-Based Vetericyn™ Wound Spray

January 24, 2008
Oculus Innovative Sciences Awarded Damages by Federal Court in Intellectual Property Rights Litigation

January 22, 2008
Top-Line Data from Oculus Innovative Sciences' Phase II Trial to Be Presented at DFCon 08 (Diabetic Foot Global Conference) on March 14, 2008

January 17, 2008
Oculus Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors

January 3, 2008
Oculus Innovative Sciences Completes Patient Treatment and Follow-up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers

December 18, 2007
Oculus Innovative Sciences Announces Completion of Two Randomized Controlled Clinical Trials of Microcyn® Technology in China

December 5, 2007
Oculus Innovative Sciences Completes Enrollment of Phase II Trial of Microcyn® Technology in Treatment of Mildly Infected Diabetic Foot Ulcers

November 19, 2007
Oculus Innovative Sciences Wins Federal Court Ruling in Intellectual Property Rights Litigation

November 12, 2007
Oculus Innovative Sciences Announces Fiscal Second Quarter 2008 Quarterly Results and Clinical Update

November 8, 2007
Oculus Innovative Sciences Schedules Fiscal Second Quarter 2008 Financial Results Release and Conference Call

November 1, 2007
Oculus Innovative Sciences to Present at SMH Capital Markets Investor Growth Conference

October 30, 2007
Oculus Innovative Sciences to Present at Acumen BioFin 9th Annual Healthcare Conference

October 3, 2007
Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference

September 17, 2007
Oculus Innovative Sciences Microcyn Technology Data to be Presented by Researchers at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

September 17, 2007
Oculus Innovative Sciences Provides Update of Phase II Study for Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

September 14, 2007
Oculus Innovative Sciences to Conduct Conference Call Update on Phase II Study of Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

September 6, 2007
Oculus Innovative Sciences to Present at First Albany Capital Regenerative Technologies Conference

August 29, 2007
Oculus Innovative Sciences to Present at Roth Capital Partners 2007 New York Conference

August 9, 2007
Oculus Innovative Sciences Announces Fiscal First Quarter 2008 Financial Results

August 8, 2007
Oculus Innovative Sciences Announces $10.1 Million Private Placement of Common Stock

August 3, 2007
Oculus Innovative Sciences Schedules Fiscal First Quarter 2008 Financial Results Release and Conference Call

June 26, 2007
Oculus Innovative Sciences Announces Results From Anti-Inflammatory Study Using Microcyn® Technology

June 18, 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality

June 13, 2007
Drug Enhancement Company of America Licenses Oculus' Microcyn® Technology for Use in First Responder ''Pen-Like'' Applicator

June 7, 2007
Oculus Announces Fiscal Fourth Quarter and Full Year 2007 Financial Results

June 6, 2007
Oculus Schedules Fiscal Fourth Quarter and Full Year 2007 Financial Results Release and Conference Call

Microcyn60™ is now available at all major pharmacies throughout Mexico.

September 2006
Wounds
Super-Oxidized Solution (SOS) Therapy for Infected Diabetic Foot Ulcers
(PDF: 256 KB)

August 2006
Podiatry Today
Emerging Innovations In Treatment
(PDF: 244 KB)

January 2006
Wounds
Clinical Experience with a New, Stable, Super-Oxidized Water in Wound Treatment
(PDF: 528 KB)

More »

...........................................





 

Microcyn60The Microcyn® Technology platform was first introduced in Mexico in 2003. The Mexican Ministry of Health approved Microcyn® as a disinfectant and antiseptic in July of that same year, and then as a sterilant in November.

Many key medical opinion leaders in Mexico and Europe have tested and validated the Microcyn® Technology’s efficacy and safety. It has received CE mark approval in Europe for treatment of acute and chronic wounds as well as two United States FDA 510K clearances to moisten, lubricate, cleanse and debride wounds and burns.

Microcyn® Technology is initially being used in the treatment of complex wounds, such as burns and diabetic foot ulcers, in which infection can pose significant danger to the patient. While in-vitro studies have shown that Microcyn® can effectively eradicate bacteria, numerous in-vivo studies have also confirmed the same bacteria-eradicating results in open wounds. In numerous third-party case studies conducted to date by individual physicians, the use of both systemic and dermal antibiotics has been significantly reduced when Microcyn® Technology was used. The results of a 64-patient study in burn patients were presented at the Texas Surgical Society in April 2005.


Diabetic Foot Ulcers

Diabetic foot ulcers treated with Microcyn® Technology as part of a comprehensive treatment regimen have shown both elimination of the fetid odor as well as clinical benefits with respect to the reduction of cellulitis and tissue toxicity. Patients that in the past might have had to undergone radical procedures such as amputation, are now being healed and their limbs saved. The Microcyn® Technology has been used in Mexico, Europe and India on several hundred patients for treatment of diabetic ulcers with excellent results. Diabetic ulcers are considered a complex wound in which many factors can influence or delay wound healing. These factors include, but are not limited to, vascular health, insulin levels and dietary controls among others. In all cases, the comprehensive regimen with Microcyn® Technology has shown to effectively eradicate both infection and the fetid odor, while facilitating enhanced wound healing.


Burns

Second- and third-degree burns are very challenging due to the high risk of infection since the skin is no longer a barrier to infection. As well, skin grafts offer potential for a number of complications. A graft "takes" or is successful when new blood vessels and tissue form in the injured area. Sometimes, skin grafts do not take because of early complications such as infection, which is the most common cause of graft failure. Based upon the results from a clinical study conducted at the Guadalajara Civil
Hospital, when patients are treated with Microcyn® Technology in a comprehensive treatment program, healing of the burns is accelerated, the levels of pain and infection reduced and the patient hospital stay is significantly reduced.

Varicose Vein Leg Ulcers

Stasis ulcers oftentimes present a devastating lifestyle. The pain is constant and the odor horrific. These patients live with both the pain and decaying stench 24 hours a day, seven days a week—many for the greater part of their lives. The degree of ulceration is oftentimes exacerbated by a general neglect of the wound that can be the result of limited access to modern medical care.

Compounding this is the fact that invading bacteria can grow resistant in reaction to antibiotics that are used to treat the ulcer. Conventional antiseptics provide some relief against most bacteria. However, many antiseptics can actually induce damage to the healthy tissue surrounding these ulcers. It is a real dilemma since what is typically used in an attempt to prevent infection may end up causing even greater harm to the patient.

Within a few weeks after first treating patients with the Microcyn® Technology regimen, physicians begin to see healing in decades-old ulcers that was previously unheard of. The photos below graphically illustrate the significant results achieved on these ulcers when treated with a Microcyn® Technology-based regimen.

 

NOTE: Microcyn® does not have U.S. FDA clearance for claims other than to moisten, lubricate, cleanse and debride wounds.